Fungal infection drug for lung transplant recipients may increase cancer, death risk
the ONA take:
A prescription drug that is commonly used to treat fungal infections in lung transplant recipients may significantly increase the risk for skin cancer and even death, according to a recent study published in the American Journal of Transplantation.
Researchers led by Sarah Arron, MD, PhD, of the UCSF High Risk Skin Cancer Clinic looked at 455 single-, double- or heart-lung transplant recipients who received their transplant between October 1991 to December 2012.
Patients were analyzed for voriconazole exposure and its impact on cutaneous squamous cell carcinoma and mortality compared to the general population.
They found that exposure to the drug resulted in a 73% greater risk for SCC, with each additional 30-day exposure increasing the risk by 3%.
While the drug significantly reduced risk of Aspergillus colonization, especially within the first year of transplantation along with a reduced all-cause mortality in these patients, it did not reduce risk of aspergillosis.
“It is important for physicians to be aware of the impact of voriconzaole on these outcomes,” said Dr. Arron. “We recommend that all providers counsel lung transplant recipients on skin cancer risk and photoprotection in addition to scheduling routine skin cancer screening with a trained dermatologist after transplantation.”
Prescription drug that is commonly used to treat fungal infections in lung transplant recipients may significantly increase the risk for skin cancer.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|